Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00791557 · ClinicalTrials.gov registry record · NA
Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease
A NA study, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT00791557 is a NA study that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 2 participants.
The verdict
NCT00791557, a NA study, has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
Subjects must be 18- 75 years old and have a history of both inflammatory bowels disease (Crohn's or ulcerative colitis) and pyoderma gangrenosum. This is a 6 month open label study of an intravenous (IV) medication. Visits occur every 2 weeks initially, then every 1-2 months later in the study.
Interventions
- DRUG Infliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2008-10 |
| Est. Completion | 2010-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00791557
The ClinicalTrials.gov registry entry for NCT00791557 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Infliximab is the first listed.
NCT00791557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00791557 about?
NCT00791557 is a clinical study titled "Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease". Subjects must be 18- 75 years old and have a history of both inflammatory bowels disease (Crohn's or ulcerative colitis) and pyoderma gangrenosum. This is a 6 month open label study of an intravenous (IV) medication. Visits occur every 2 weeks initially, then every 1-2 months later in the study.
What is the current status of trial NCT00791557?
This trial is currently completed. It is a NA study. The enrollment target is 2 participants. The study started on 2008-10. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00791557?
The interventions under investigation include: Infliximab (DRUG).
Who is sponsoring clinical trial NCT00791557?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.